Trastuzumab emtansine for patients with non–small cell lung cancer positive for human epidermal growth factor receptor 2 exon-20 insertion mutationsEiji Iwama, Isamu Okamoto, Yoichi Nakanishi et al.|European Journal of Cancer|2021Cited by 77
Activity and safety of atezolizumab plus carboplatin and paclitaxel in patients with advanced or recurrent thymic carcinoma (MARBLE): a multicentre, single-arm, phase 2 trialTakehito Shukuya, Kazuhisa Takahashi, Tetsuhiko Asao et al.|The Lancet Oncology|2025Cited by 20
P89.06 Prospective Concordance Study of a Multi-Gene PCR Assay and NGS for the Detection of Targetable Gene Alterations in Lung CancerShingo Matsumoto, Kōichi Goto, Takaya Ikeda et al.|Journal of Thoracic Oncology|2021Cited by 7
Study Design and Rationale for Marble Study: A Phase II Trial of Atezolizumab (MPDL3280A) Plus Carboplatin and Paclitaxel in Patients With Advanced or Recurrent Thymic Carcinoma (JTD2101)Tetsuhiko Asao, Kazuhisa Takahashi, Takehito Shukuya et al.|Clinical Lung Cancer|2023Cited by 5
Biological impact of chemotherapy during treatment with EGFR tyrosine kinase inhibitors for non-small cell lung cancer positive for EGFR activating mutationsEiji Iwama, Isamu Okamoto, Kazuko Sakai et al.|Lung Cancer|2025Cited by 3